14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
WORX vs NRC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, National Research Corporation (NRC) is the stronger overall head-to-head candidate over SC WORX Corp (WORX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). WORX carries a Unified Composite Score of 34.1/100 (SELL) at $1.15 (N/M Forward P/E, -20.1% operating margin), whereas NRC carries 32.4/100 (SELL) at $26.33 (24.8x Forward P/E, 13.4% operating margin).
Composite vs. Pillar Nuance: While WORX currently prints a higher short-term Unified Composite Score (34.1/100 SELL vs. NRC 32.4/100 SELL), NRC captures the overall institutional head-to-head verdict (9–1 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (13.4% vs. -20.1% operating margin) and revenue trajectory (+11.0% vs. +3.4% YoY).
Defensive Composite Rating Caution: Although NRC compares more favorably head-to-head, both WORX (34.1/100 SELL) and NRC (32.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on WORX vs NRC. Trailing 12-month operating profitability (WORX -20.1% vs NRC 13.4%) and valuation multiples (WORX N/M vs NRC 24.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Health Information Services value chain with $1.7M market capitalization and -20.1% operating margin.
OpEx & R&D Reinvestment64.8% of Rev ($1.9M)
90D Engineering Disclosures0 Published
NRC Moat ProfileHigh-Margin Pricing Power Moat
Health Information Services Operator
Competes within the Health Information Services value chain with $563.6M market capitalization and 13.4% operating margin.
OpEx & R&D Reinvestment47.3% of Rev ($68M)
90D Engineering Disclosures0 Published
Investor FAQ WORX vs NRC Key Questions & Quantitative Answers
As of Nov 16, 2026, National Research Corporation (NRC) is the stronger overall head-to-head candidate over SC WORX Corp (WORX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). WORX carries a Unified Composite Score of 34.1/100 (SELL) at $1.15 (N/M Forward P/E, -20.1% operating margin), whereas NRC carries 32.4/100 (SELL) at $26.33 (24.8x Forward P/E, 13.4% operating margin). Composite vs. Pillar Nuance: While WORX currently prints a higher short-term Unified Composite Score (34.1/100 SELL vs. NRC 32.4/100 SELL), NRC captures the overall institutional head-to-head verdict (9–1 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (13.4% vs. -20.1% operating margin) and revenue trajectory (+11.0% vs. +3.4% YoY). Defensive Composite Rating Caution: Although NRC compares more favorably head-to-head, both WORX (34.1/100 SELL) and NRC (32.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
NRC leads the Growth & Scale pillar: WORX posts +3.4% YoY revenue growth and +0.0% YoY earnings growth on $2.9M TTM revenue (44.7% gross margin, -20.1% operating margin), compared with NRC at +11.0% YoY revenue growth and +16.7% YoY earnings growth on $144M TTM revenue (60.7% gross margin, 13.4% operating margin). On trailing 12-month operating scale, WORX generates $2.9M in USD-normalized revenue versus $144M for NRC. In operating R&D and SG&A reinvestment, WORX deploys 64.8% of Rev ($1.9M) (0 90-day corporate R&D disclosures) versus 47.3% of Rev ($68M) (0 disclosures) for NRC.
NRC screens cheaper on headline valuation multiples. WORX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.6x EV/Revenue (-31.2% FCF margin), whereas NRC trades at 24.8x Forward P/E, 98.4x Trailing P/E, 1.32x PEG, and 3.9x EV/Revenue (19.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against WORX (-38.1% ROE) versus NRC (248.1% ROE) capital efficiency.
In options market volatility and institutional positioning, WORX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (23.01β · 208% Vol realized risk). By comparison, NRC carries 98.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.64β · 61% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.